Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
ChiCTR2100044045Phase 4Recruiting
- Sponsor
- Mianyang Hospital of Traditional Chinese Medicine
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), ankylosing spondylitis (AS), plaque psoriasis and 1 more, sponsored by Mianyang Hospital of Traditional Chinese Medicine. Primary endpoint: EuroQoL-5 Dimension (EQ-5D). Started Mar 2021; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)plaque psoriasisautoimmune inflammatory diseases
Beyond the preview
Go deeper on ChiCTR2100044045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044045.